Aethlon medical publishes in vitro studies demonstrating hemopurifier resin binding of seven clinically relevant covid-19 variants

Viral capture efficiency ranged from 53% to 89% for the seven covid-19 variants tested san diego, may 2, 2022 /prnewswire/ -- aethlon medical, inc. (nasdaq: aemd), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced the publication of a pre-print manuscript featuring data that demonstrated aethlon's proprietary gna affinity resin was able to bind seven clinically relevant sars-cov-2 variants in vitro, including the delta and omicron variants. viral capture efficiency with the gna affinity resin ranged from 53% to 89% for all variants tested.
AEMD Ratings Summary
AEMD Quant Ranking